Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2023 | May 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2023 · Filed May 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.73 · Expires 2033-04-30 | Direct | 3,481 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 3,481 · Balance 3,481 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 3, 2023 20:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,481 | $0.00 Strike: $342.73 | $0.00 |
DisclosureSEC source: 0001209191-23-027034 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,481 Underlying: Common Stock · 3,481 shares Expires 2033-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,429 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $323.33 | $25,866.40 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 970 | $322.20 | $312,534.00 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,955 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $322.20 (range $321.75 to $322.74). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 379 | $321.31 | $121,776.49 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,925 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $321.31 (range $320.62 to $321.59). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,429 | $72.14 | $103,088.06 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · derivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 680 | $320.94 | $218,239.20 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $320.94 (range $320.89 to $320.99). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $320.25 | $128,100.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 10 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,555 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $320.25 (range $319.80 to $320.77). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 478 | $319.25 | $152,601.50 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,955 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $319.25 (range $318.79 to $319.56). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $317.95 | $317,950.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,433 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $317.95 (range $317.43 to $318.35). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,140 | $316.82 | $361,174.80 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,433 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $316.82 (range $316.23 to $317.16). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 302 | $315.42 | $95,256.84 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,573 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $315.42 (range $315.23 to $315.66). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · derivative · entry 12 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,429 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 579 | $314.95 | $182,356.05 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $314.95 (range $314.58 to $315.14). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,621 | $314.10 | $823,256.10 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $314.10 (range $313.53 to $314.50). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $312.80 | $250,240.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,075 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $312.80 (range $312.41 to $313.06). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · derivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,429 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,489 | $313.36 | $466,593.04 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $313.36 (range $313.00 to $313.73). Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,511 | $312.29 | $784,160.19 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,364 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $312.29 (range $312.00 to $312.92). Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,129 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · derivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,429 Underlying: Common Stock · 2,129 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,129 | $312.02 | $664,290.58 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $312.02 (range $312.00 to $312.17). Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,129 | $72.14 | $153,586.06 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 442 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · derivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,558 Underlying: Common Stock · 442 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 442 | $312.17 | $137,979.14 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $312.17 (range $312.00 to $312.53). Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 442 | $72.14 | $31,885.88 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,000 | $312.03 | $1,248,120.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $312.03 (range $312.00 to $312.14). Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 4,462 | $0.00 Strike: $276.17 | $0.00 |
DisclosureSEC source: 0000899243-22-016342 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,462 Underlying: Common Stock · 4,462 shares Expires 2032-04-30 Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0000899243-22-015163 · doc4.xml · derivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 119 | $286.80 | $34,129.20 |
DisclosureSEC source: 0000899243-22-015163 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $286.80 (range $286.68 to $286.82). Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 491 | $285.16 | $140,013.56 |
DisclosureSEC source: 0000899243-22-015163 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $285.16 (range $284.88 to $285.63). Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,008 | $284.06 | $286,332.48 |
DisclosureSEC source: 0000899243-22-015163 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,485 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $284.06 (range $283.72 to $284.46). Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 382 | $282.70 | $107,991.40 |
DisclosureSEC source: 0000899243-22-015163 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,493 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $282.70 (range $282.40 to $283.15). Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $81.54 | $163,080.00 |
DisclosureSEC source: 0000899243-22-015163 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0000899243-22-014962 · doc4.xml · derivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $291.18 | $116,472.00 |
DisclosureSEC source: 0000899243-22-014962 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $291.18 (range $290.80 to $291.64). Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $289.84 | $115,936.00 |
DisclosureSEC source: 0000899243-22-014962 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,275 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $289.84 (range $289.69 to $289.96). Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 252 | $288.92 | $72,807.84 |
DisclosureSEC source: 0000899243-22-014962 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,675 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.92 (range $288.51 to $289.24). Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 948 | $287.87 | $272,900.76 |
DisclosureSEC source: 0000899243-22-014962 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,927 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.87 (range $287.49 to $288.26). Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $81.54 | $163,080.00 |
DisclosureSEC source: 0000899243-22-014962 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0000899243-22-014804 · doc4.xml · derivative · entry 16 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 354 | $291.12 | $103,056.48 |
DisclosureSEC source: 0000899243-22-014804 · doc4.xml · nonDerivative · entry 14 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $291.12 (range $290.80 to $291.42). Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $290.17 | $58,034.00 |
DisclosureSEC source: 0000899243-22-014804 · doc4.xml · nonDerivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,229 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $290.17 (range $289.72 to $290.62). Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $288.55 | $115,420.00 |
DisclosureSEC source: 0000899243-22-014804 · doc4.xml · nonDerivative · entry 12 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,429 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $288.55 (range $288.23 to $289.11). Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $287.42 | $57,484.00 |
DisclosureSEC source: 0000899243-22-014804 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,829 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $287.42 (range $287.02 to $287.83). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.